Interactions between zantac-75(ranitidine) and Baraclude (entecavir)
ranitidine and entecavir (Moderate Drug-Drug)
MONITOR: Theoretically, the coadministration of entecavir with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of entecavir and/or the coadministered drug(s). The mechanism is competitive inhibition of renal excretion. Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, tenofovir, valacyclovir, ganciclovir, and valganciclovir.
MANAGEMENT: Patients receiving entecavir in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.
